Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
30 05 2023
30 05 2023
Historique:
received:
18
04
2022
accepted:
11
05
2023
medline:
1
6
2023
pubmed:
31
5
2023
entrez:
30
5
2023
Statut:
epublish
Résumé
Clinical management of breast cancer (BC) metastasis remains an unmet need as it accounts for 90% of BC-associated mortality. Although the luminal subtype, which represents >70% of BC cases, is generally associated with a favorable outcome, it is susceptible to metastatic relapse as late as 15 years after treatment discontinuation. Seeking therapeutic approaches as well as screening tools to properly identify those patients with a higher risk of recurrence is therefore essential. Here, we report that the lipid-degrading enzyme fatty acid amide hydrolase (FAAH) is a predictor of long-term survival in patients with luminal BC, and that it blocks tumor progression and lung metastasis in cell and mouse models of BC. Together, our findings highlight the potential of FAAH as a biomarker with prognostic value in luminal BC and as a therapeutic target in metastatic disease.
Identifiants
pubmed: 37253733
doi: 10.1038/s41467-023-38750-9
pii: 10.1038/s41467-023-38750-9
pmc: PMC10229544
doi:
Substances chimiques
Amidohydrolases
EC 3.5.-
Biomarkers, Tumor
0
fatty-acid amide hydrolase
EC 3.5.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3130Informations de copyright
© 2023. The Author(s).
Références
Breast Cancer Res Treat. 2012 Feb;131(3):765-75
pubmed: 21452023
Physiol Rev. 2016 Oct;96(4):1593-659
pubmed: 27630175
Genome Biol. 2014;15(12):550
pubmed: 25516281
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
N Engl J Med. 2017 Nov 9;377(19):1836-1846
pubmed: 29117498
PLoS One. 2011;6(6):e20610
pubmed: 21713035
Sci Rep. 2017 Jan 23;7:41121
pubmed: 28112243
Trends Mol Med. 2020 Mar;26(3):263-272
pubmed: 31822395
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9371-6
pubmed: 11470906
Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6740-5
pubmed: 17420468
Nature. 2019 Mar;567(7748):399-404
pubmed: 30867590
Cell Mol Life Sci. 2012 Dec;69(24):4177-90
pubmed: 22802127
Cancer Res. 2004 Dec 1;64(23):8604-12
pubmed: 15574767
Database (Oxford). 2021 Feb 18;2021:
pubmed: 33599248
J Clin Oncol. 2018 Jul 1;36(19):1941-1948
pubmed: 29676944
Nature. 2005 Jul 28;436(7050):518-24
pubmed: 16049480
Nature. 2002 Jan 31;415(6871):530-6
pubmed: 11823860
Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10578-82
pubmed: 1359541
Cancer Res. 2008 Feb 15;68(4):989-97
pubmed: 18281472
Transl Med UniSa. 2014 Apr 08;10:8-12
pubmed: 25147760
Oncogene. 2006 Apr 6;25(15):2273-84
pubmed: 16288205
Pharmacol Rev. 2006 Sep;58(3):389-462
pubmed: 16968947
Int J Cancer. 2011 Jul 1;129(1):225-32
pubmed: 20830712
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Nat Med. 2009 Aug;15(8):907-13
pubmed: 19648928
Nat Rev Clin Oncol. 2019 May;16(5):296-311
pubmed: 30563978
Oncoscience. 2014 Apr 30;1(4):272-282
pubmed: 25594019
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13820-5
pubmed: 19666588
FASEB J. 2015 Mar;29(3):1056-68
pubmed: 25466898
Lancet. 2005 Feb 19-25;365(9460):671-9
pubmed: 15721472
J Surg Res. 2009 Aug;155(2):231-6
pubmed: 19482312
J Clin Oncol. 2009 Mar 10;27(8):1160-7
pubmed: 19204204
Mol Cancer. 2010 Jul 22;9:196
pubmed: 20649976
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nucleic Acids Res. 2009 Jan;37(Database issue):D674-9
pubmed: 18832364
Nat Rev Cancer. 2012 May 04;12(6):436-44
pubmed: 22555283
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10335-40
pubmed: 12149457
Eur J Cancer. 2012 Nov;48(16):3112-22
pubmed: 22425263
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8375-80
pubmed: 9653194
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
J Intern Med. 2021 Jul;290(1):2-26
pubmed: 33348434
Breast Cancer. 2018 Nov;25(6):639-649
pubmed: 29786773
Exp Cell Res. 2006 Feb 15;312(4):363-73
pubmed: 16343481
Cancer Cell. 2003 Jun;3(6):537-49
pubmed: 12842083
Cancer Cell. 2006 Dec;10(6):515-27
pubmed: 17157791
J Natl Cancer Inst. 2015 Apr 08;107(6):djv077
pubmed: 25855725
Cancer Res. 2005 Feb 1;65(3):967-71
pubmed: 15705897
Comput Struct Biotechnol J. 2021 Jul 18;19:4101-4109
pubmed: 34527184
Database (Oxford). 2016 Jul 03;2016:
pubmed: 27374120
N Engl J Med. 2002 Dec 19;347(25):1999-2009
pubmed: 12490681
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
Nature. 2001 Mar 1;410(6824):50-6
pubmed: 11242036
PLoS One. 2012;7(2):e30979
pubmed: 22347416
Genome Biol. 2007;8(5):R76
pubmed: 17493263
Pharmacol Rev. 2010 Dec;62(4):588-631
pubmed: 21079038
Front Genet. 2019 Sep 25;10:858
pubmed: 31608109
Nat Commun. 2018 Apr 10;9(1):1366
pubmed: 29636450
Br J Pharmacol. 2018 Jul;175(13):2566-2580
pubmed: 29663308
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15901-5
pubmed: 14665696
Eur J Biochem. 1998 Jun 15;254(3):634-42
pubmed: 9688276